Chai Discovery vs EvolutionaryScale

Last VerifiedAugust 4, 2026
Verdict

The two best governed companies in protein design, which matters because this is the one category in the index where the governance question is biosecurity rather than bias. EvolutionaryScale published its flagship model in a major peer reviewed journal, offers the widest access routes including holding the weights yourself, and publishes the most substantive position anywhere here on the risk that designing novel proteins creates. Chai releases named, versioned models with a documented history, quantifies its wet laboratory validation including how many targets were attempted and how many designs tested, and backs its governance position with a costly action rather than a statement. Both are unusually open for this field. Neither has a therapeutic established in humans, so read the excellent molecular evidence as exactly that.

Select Chai Discovery if
  • Models are named, versioned and released publicly with a documented history, and the underlying method is described specifically rather than as generative machine learning.
  • Wet laboratory validation is quantified with its design stated, including how many targets were attempted and how many designs tested.
  • The governance posture is the most complete in this category and is backed by a costly action rather than a policy statement.
Select EvolutionaryScale if
  • The flagship model appears in a major peer reviewed journal, so the method passed external review rather than a demonstration.
  • The widest access in this category and the only route where a user can hold the weights, which changes the dependency entirely.
  • It publishes a substantive position on the biosecurity risk that designing novel proteins creates, rather than generic principles.
Attribute Matrix

Side by Side

Axis
C
Chai Discovery
E
EvolutionaryScale
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage
Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.

Disclosure

These two hold the strongest governance positions in a category where the governance question is biosecurity rather than bias, and that is the axis to compare them on rather than benchmark performance. Neither holds a located security attestation. Molecular evidence and clinical evidence are different things on both records: excellent laboratory validation exists and no therapeutic from either has been established in humans, so neither should be read as a clinical stage proposition. Neither publishes pricing, and the access models differ enough that a commercial comparison requires knowing which route you intend to take.

AI Health Index

An independent reference for evaluating AI vendors in healthcare. No vendor pays for inclusion, placement, or rating.

Index Status
Last index update
August 4, 2026
The AI Health Index is an editorial reference, not a regulatory body. Vendor data is verified against published sources and public regulatory filings. Figures labeled “Estimated” have not been confirmed by the vendor. See the Methodology page for evaluation standards and limitations.
© 2026 AI Health Index
3801 N Capital of Texas Hwy, Ste E240 · Austin, TX 78746